Cargando…
Treatment of crow’s feet lines and forehead lines with Botox (onabotulinumtoxinA): Development, insights, and impact
Extrinsic and age-related intrinsic factors contribute to the development of facial lines, including lateral canthal lines (called crow’s feet lines [CFL]) and horizontal forehead lines (FHL). OnabotulinumtoxinA is a highly effective treatment for facial lines that inhibits acetylcholine release at...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374187/ https://www.ncbi.nlm.nih.gov/pubmed/37499083 http://dx.doi.org/10.1097/MD.0000000000032496 |
_version_ | 1785078723064627200 |
---|---|
author | Carruthers, Alastair Carruthers, Jean De Boulle, Koenraad Lowe, Nicholas Lee, Elisabeth Brin, Mitchell F. |
author_facet | Carruthers, Alastair Carruthers, Jean De Boulle, Koenraad Lowe, Nicholas Lee, Elisabeth Brin, Mitchell F. |
author_sort | Carruthers, Alastair |
collection | PubMed |
description | Extrinsic and age-related intrinsic factors contribute to the development of facial lines, including lateral canthal lines (called crow’s feet lines [CFL]) and horizontal forehead lines (FHL). OnabotulinumtoxinA is a highly effective treatment for facial lines that inhibits acetylcholine release at the neuromuscular junction. This temporary chemical denervation leads to localized muscle relaxation and subsequent wrinkle reduction. Early studies of onabotulinumtoxinA treatment for facial neuronal disorders such as dystonia documented improvements in FHL and CFL. After the neurotoxin was approved for treating frown lines (glabellar lines [GL]), individuals requested treatment for other rhytids, and physicians continued assessing use in new areas. Once onabotulinumtoxinA was in clinical trial development, its efficacy and safety for CFL and FHL were successively evaluated as required by the US Food and Drug Administration and by key global health authorities, including those in the European Union, Japan, and China. Allergan, collaborating with leading physicians, established clinical programs that included novel safety and efficacy measures to meet regulatory requirements. Global, phase 3, randomized, controlled studies of CFL and FHL met rigorous primary endpoints. Some countries mandated clinical trial data beyond US and European regulations, and Allergan conducted 11 studies in total, fulfilling diverse regulatory and study population data requirements. Adverse events associated with local spread, including brow and eyelid ptosis, diplopia, headache, and eyelid sensory disorder, were infrequent and well tolerated. Consequently, onabotulinumtoxinA treatment of upper facial lines is now established globally as a highly effective, minimally invasive treatment for patients to achieve a natural appearance and look younger. |
format | Online Article Text |
id | pubmed-10374187 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-103741872023-07-28 Treatment of crow’s feet lines and forehead lines with Botox (onabotulinumtoxinA): Development, insights, and impact Carruthers, Alastair Carruthers, Jean De Boulle, Koenraad Lowe, Nicholas Lee, Elisabeth Brin, Mitchell F. Medicine (Baltimore) OA Supplement Article Extrinsic and age-related intrinsic factors contribute to the development of facial lines, including lateral canthal lines (called crow’s feet lines [CFL]) and horizontal forehead lines (FHL). OnabotulinumtoxinA is a highly effective treatment for facial lines that inhibits acetylcholine release at the neuromuscular junction. This temporary chemical denervation leads to localized muscle relaxation and subsequent wrinkle reduction. Early studies of onabotulinumtoxinA treatment for facial neuronal disorders such as dystonia documented improvements in FHL and CFL. After the neurotoxin was approved for treating frown lines (glabellar lines [GL]), individuals requested treatment for other rhytids, and physicians continued assessing use in new areas. Once onabotulinumtoxinA was in clinical trial development, its efficacy and safety for CFL and FHL were successively evaluated as required by the US Food and Drug Administration and by key global health authorities, including those in the European Union, Japan, and China. Allergan, collaborating with leading physicians, established clinical programs that included novel safety and efficacy measures to meet regulatory requirements. Global, phase 3, randomized, controlled studies of CFL and FHL met rigorous primary endpoints. Some countries mandated clinical trial data beyond US and European regulations, and Allergan conducted 11 studies in total, fulfilling diverse regulatory and study population data requirements. Adverse events associated with local spread, including brow and eyelid ptosis, diplopia, headache, and eyelid sensory disorder, were infrequent and well tolerated. Consequently, onabotulinumtoxinA treatment of upper facial lines is now established globally as a highly effective, minimally invasive treatment for patients to achieve a natural appearance and look younger. Lippincott Williams & Wilkins 2023-07-01 /pmc/articles/PMC10374187/ /pubmed/37499083 http://dx.doi.org/10.1097/MD.0000000000032496 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | OA Supplement Article Carruthers, Alastair Carruthers, Jean De Boulle, Koenraad Lowe, Nicholas Lee, Elisabeth Brin, Mitchell F. Treatment of crow’s feet lines and forehead lines with Botox (onabotulinumtoxinA): Development, insights, and impact |
title | Treatment of crow’s feet lines and forehead lines with Botox (onabotulinumtoxinA): Development, insights, and impact |
title_full | Treatment of crow’s feet lines and forehead lines with Botox (onabotulinumtoxinA): Development, insights, and impact |
title_fullStr | Treatment of crow’s feet lines and forehead lines with Botox (onabotulinumtoxinA): Development, insights, and impact |
title_full_unstemmed | Treatment of crow’s feet lines and forehead lines with Botox (onabotulinumtoxinA): Development, insights, and impact |
title_short | Treatment of crow’s feet lines and forehead lines with Botox (onabotulinumtoxinA): Development, insights, and impact |
title_sort | treatment of crow’s feet lines and forehead lines with botox (onabotulinumtoxina): development, insights, and impact |
topic | OA Supplement Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374187/ https://www.ncbi.nlm.nih.gov/pubmed/37499083 http://dx.doi.org/10.1097/MD.0000000000032496 |
work_keys_str_mv | AT carruthersalastair treatmentofcrowsfeetlinesandforeheadlineswithbotoxonabotulinumtoxinadevelopmentinsightsandimpact AT carruthersjean treatmentofcrowsfeetlinesandforeheadlineswithbotoxonabotulinumtoxinadevelopmentinsightsandimpact AT deboullekoenraad treatmentofcrowsfeetlinesandforeheadlineswithbotoxonabotulinumtoxinadevelopmentinsightsandimpact AT lowenicholas treatmentofcrowsfeetlinesandforeheadlineswithbotoxonabotulinumtoxinadevelopmentinsightsandimpact AT leeelisabeth treatmentofcrowsfeetlinesandforeheadlineswithbotoxonabotulinumtoxinadevelopmentinsightsandimpact AT brinmitchellf treatmentofcrowsfeetlinesandforeheadlineswithbotoxonabotulinumtoxinadevelopmentinsightsandimpact |